Biochemical evidence for conformational variants in the anti-viral and pro-metastatic protein IFITM1
Author:
Nekulová Marta1ORCID, Wyszkowska Marta2, Friedlová Nela13, Uhrík Lukáš1, Zavadil Kokáš Filip1, Hrabal Václav13, Hernychová Lenka1, Vojtěšek Bořivoj1, Hupp Ted R.4, Szymański Michał R.2
Affiliation:
1. Research Centre for Applied Molecular Oncology , Masaryk Memorial Cancer Institute , 656 53 Brno , Czech Republic 2. Structural Biology Laboratory, Intercollegiate Faculty of Biotechnology of University of Gdansk and Medical University of Gdansk , University of Gdansk , 80-307 Gdansk , Poland 3. Department of Experimental Biology, Faculty of Science , Masaryk University , 625 00 Brno , Czech Republic 4. Institute of Genetics and Molecular Medicine , University of Edinburgh , EH4 2XR Edinburgh , UK
Abstract
Abstract
Interferon induced transmembrane proteins (IFITMs) play a dual role in the restriction of RNA viruses and in cancer progression, yet the mechanism of their action remains unknown. Currently, there is no data about the basic biochemical features or biophysical properties of the IFITM1 protein. In this work, we report on description and biochemical characterization of three conformational variants/oligomeric species of recombinant IFITM1 protein derived from an Escherichia coli expression system. The protein was extracted from the membrane fraction, affinity purified, and separated by size exclusion chromatography where two distinct oligomeric species were observed in addition to the expected monomer. These species remained stable upon re-chromatography and were designated as “dimer” and “oligomer” according to their estimated molecular weight. The dimer was found to be less stable compared to the oligomer using circular dichroism thermal denaturation and incubation with a reducing agent. A two-site ELISA and HDX mass spectrometry suggested the existence of structural motif within the N-terminal part of IFITM1 which might be significant in oligomer formation. Together, these data show the unusual propensity of recombinant IFITM1 to naturally assemble into very stable oligomeric species whose study might shed light on IFITM1 anti-viral and pro-oncogenic functions in cells.
Funder
European Regional Development Fund Czech Science Foundation Ministry of Health, Czech Republic BBSRC RASOR consortium Ministry of Education and Science, Poland EMBO Installation Grant
Publisher
Walter de Gruyter GmbH
Reference35 articles.
1. Bailey, C.C., Zhong, G., Huang, I.-C., and Farzan, M. (2014). IFITM-family proteins: the cell’s first line of antiviral defense. Annu. Rev. Virol. 1: 261–283, https://doi.org/10.1146/annurev-virology-031413-085537. 2. Brass, A.L., Huang, I.-C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J., Weyer, J.L., Van Der Weyden, L., Fikrig, E., et al.. (2009). The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, west nile virus, and dengue virus. Cell 139: 1243–1254, https://doi.org/10.1016/j.cell.2009.12.017. 3. Chesarino, N.M., McMichael, T.M., and Yount, J.S. (2014). Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol. 9: 1151–1163, https://doi.org/10.2217/fmb.14.65. 4. Chmielewska, A.M., Gómez-Herranz, M., Gach, P., Nekulova, M., Bagnucka, M.A., Lipińska, A.D., Rychłowski, M., Hoffmann, W., Król, E., Vojtesek, B., et al.. (2022). The role of IFITM proteins in tick-borne encephalitis virus infection. J. Virol. 96: e01130-21, https://doi.org/10.1128/jvi.01130-21. 5. Diamond, M.S. and Farzan, M. (2013). The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13: 46–57, https://doi.org/10.1038/nri3344.
|
|